EARS Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Jul 2021 @ 00:00):

Auris Medical Holding Ltd. engages in the development of novel products that address unmet medical needs in neurotology and central nervous system disorders...

Stats
Today's Volume	174 066
Average Volume	1.89M
Market Cap	4.21M
Last Dividend	CHF0 ( N/A )
Next Dividend	CHF0 ( N/A )
P/E	-2.05
ATR14	CHF0.243 (7.98%)

Volume Correlation

Long: 0.48 (neutral)

Short: 0.85 (strong)

Signal:(42.109) Same movement expected

Auris Medical Holding Ltd Correlation

10 Most Positive Correlations
EDAP	0.86
EDRY	0.853
PAYS	0.852
SQQQ	0.843
BLTE	0.84
HIBB	0.836
GOGL	0.835
CHCI	0.832
WVVI	0.83
SHIP	0.827

10 Most Negative Correlations
INZY	-0.869
OSW	-0.863
VOXX	-0.859
TXRH	-0.857
CPRT	-0.855
EYEN	-0.853
QYLG	-0.851
LRGE	-0.85
IRTC	-0.85
QQQ	-0.85

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Auris Medical Holding Ltd Correlation - Currency/Commodity

0.17
( neutral )

0.19
( neutral )

0.00
( neutral )

0.45
( neutral )

0.50
( weak )

-0.13
( neutral )

Auris Medical Holding Ltd Financials

Annual	2023
Revenue:	CHF0
Gross Profit:	CHF0 (0.00 %)
EPS:	CHF-14.80

Q2	2023
Revenue:	CHF52 735.00
Gross Profit:	CHF-53 356.00 (-101.18 %)
EPS:	CHF-12.91

Q1	2023
Revenue:	CHF52 735.00
Gross Profit:	CHF-53 356.00 (-101.18 %)
EPS:	CHF-12.91

Q2	2022
Revenue:	CHF1.29M
Gross Profit:	CHF-30 361.00 (-2.34 %)
EPS:	CHF-9.98

Financial Reports:

No articles found.

Auris Medical Holding Ltd

Auris Medical Holding Ltd. engages in the development of novel products that address unmet medical needs in neurotology and central nervous system disorders. The company is headquartered in Zug, Zug and currently employs 11 full-time employees. The firm focuses on the development of intranasal betahistine for the treatment of vertigo (AM-125) and for the treatment of antipsychotic-induced weight gain and somnolence (AM-201). The betahistine program is in Phase 1 of clinical trials. Other programs in the Company's product pipeline include brimapitide-based AM-111 for the treatment of acute inner ear hearing loss and eskatemine-based Keyzilen (AM-101) for the treatment of acute inner ear tinnitus, both in Phase 3 of clinical trials, as well as AM-102 indicated for tinnitus, undergoing preclinical studies focused on selecting the lead compound. The firm operates through subsidiaries in Switzerland, Ireland and the United States.